Insmed, Inc. $INSM Shares Newly Purchased by Krilogy Financial LLC

Posted by Stanley Muller on Oct 18th, 2026

Krilogy Financial LLC acquired a new stake in Insmed, Inc. (NASDAQ:INSM – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,710 shares of the biopharmaceutical company’s stock, valued at approximately $652,000.

Several other hedge funds have also recently modified their holdings of INSM. Private Advisor Group LLC boosted its stake in shares of Insmed by 1.8% in the 1st quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 82 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Insmed by 5.4% in the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 98 shares in the last quarter. Values First Advisors Inc. grew its holdings in shares of Insmed by 7.1% in the first quarter. Values First Advisors Inc. now owns 2,203 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 146 shares in the last quarter. Reflection Asset Management purchased a new stake in shares of Insmed during the fourth quarter valued at approximately $30,000. Finally, American Trust increased its position in shares of Insmed by 12.9% during the first quarter. American Trust now owns 1,710 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 196 shares during the last quarter.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David Brennan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Insmed Stock Performance

Shares of INSM stock opened at $96.27 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The firm has a market cap of $21.02 billion, a price-to-earnings ratio of -23.42 and a beta of 0.83. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The firm’s 50-day simple moving average is $118.77 and its two-hundred day simple moving average is $118.27.

Insmed (NASDAQ:INSM – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same period in the prior year, the firm earned ($1.70) EPS. The company’s revenue was up 296.1% compared to the same quarter last year. As a group, equities analysts forecast that Insmed, Inc. will post -1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on INSM shares. UBS Group reiterated a “buy” rating on shares of Insmed in a report on Thursday, October 8th. HC Wainwright reissued a “buy” rating and issued a $220.00 price objective on shares of Insmed in a research report on Monday, October 12th. Roth Capital restated a “buy” rating and issued a $198.00 price objective (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. Wolfe Research downgraded Insmed from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $218.00 target price on shares of Insmed in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $200.30.

Read Our Latest Stock Analysis on Insmed

Insmed Company Profile

(Free Report)

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.